Abstract:Abstract Background Obefazimod (obe) is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]. Obe demonstrated efficacy in patients with UC at week-8 in a phase 2b, double-blind, placebo-controlled, dose ranging, induction trial and in the subsequent open-label maintenance (OLM) study [2]. Methods During the induction Phase 2b trial, patients received placebo or obe 25mg, 50mg or 100mg once daily (od). Irrespective of their clinical response, patients could enter the optional 96-week OLM study with obe 50mg od. Of the 222 eligible patients, 217 continued treatment in the OLM. We examine the efficacy outcomes at weeks 8, 48, and 96, for patients enrolled in the OLM according to their induction dose group. Results Among the 58 patients who initially received obe 25 mg during the induction period, 28% (16/58) achieved clinical remission at week 8. After switching to 50 mg in the OLM, the rate of clinical remission increased to 60% (35/58) at weeks 48 and 96. Similar trends were observed for clinical response (66% (38/58) at week 8, 85% (49/58) at week 48, and 74% (43/58) at week 96), endoscopic improvement (36% (21/58) at week 8, 60% (35/58) at week 48, and 66% (38/58) at week 96), and endoscopic remission (7% (4/58) at week 8, 28% (16/58) at week 48, and 47% (27/58) at week 96). In the group of patients who received obe 50 mg in the induction period (n= 51), 20% (10/51) achieved clinical remission at week 8. After switching to 50 mg in the OLM, the rate of clinical remission increased to 49% (25/51) at week 48 and 96. Similar trends were observed for clinical response and endoscopic improvement (Table 1). Among the 53 patients who received obe 100 mg in the induction period, 28% (15/53) achieved clinical remission at week 8. After switching to 50 mg in the OLM, the rate of clinical remission increased to 55% (29/53) at week 48 and week 96. Similar trends were observed for clinical response and endoscopic improvement (Table 1). Among the 55 patients who received placebo in the induction period, 15% (8/55) achieved clinical remission at week 8. After switching to 50 mg in the OLM, the rate of clinical remission increased to 55% (30/55) at week 48, and 45% (25/55) at week 96. Similar trends were observed for clinical response and endoscopic improvement (Table 1). Conclusion These findings suggest that patients with UC treated with obefazimod 50mg od after the week 8 induction period maintained efficacy and continued to improve, irrespective of their induction dose, as evidenced by higher percentages of patients reaching clinical endpoints at weeks 48 and 96 relative to week 8.

S2 Impact of Obefazimod Induction Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 8 Results from the Phase 2b Induction Trial

DOP12 Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial

DOP71 Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose

P985 Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis

DOP01 Efficacy and Safety of the IL-6 Trans-Signalling Inhibitor Olamkicept: a Phase 2 Randomized, Placebo-Controlled Trial in Moderately to Severely Active Ulcerative Colitis

Effect of Induction Therapy with Olamkicept Vs Placebo on Clinical Response in Patients with Active Ulcerative Colitis: A Randomized Clinical Trial.

P001 Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis

S744 QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis

P850 Symptomatic effectiveness of ozanimod in routine clinical care of ulcerative colitis: an interim analysis of the multicentre, prospective, noninterventional COLIBRI study

Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials

P254 Outcomes of endoscopic and histologic remission in ulcerative colitis under advanced therapy

OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial

Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

P687 Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a Phase 2/3 study (J-True North)

P901 Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trials

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

DOP54 Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapy

P879 Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A Systematic Review and Network Meta-analysis